OnKure Therapeutics (NASDAQ:OKUR) Trading Down 4.7% – Time to Sell?

OnKure Therapeutics (NASDAQ:OKUR)’s stock price dropped 4.7% on Monday . The stock traded as low as $4.81 and last traded at $4.83. Approximately 22,442 shares traded hands during trading, a decline of 75% from the average daily volume of 88,026 shares. The stock had previously closed at $5.07.

Analyst Ratings Changes

OKUR has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of OnKure Therapeutics in a report on Friday, November 8th. Leerink Partnrs raised shares of OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Leerink Partners initiated coverage on shares of OnKure Therapeutics in a report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 target price on the stock. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $36.00.

OnKure Therapeutics Stock Performance

The stock has a 50-day simple moving average of $6.35. The firm has a market cap of $16.15 million, a P/E ratio of -0.40 and a beta of 0.25.

Institutional Investors Weigh In On OnKure Therapeutics

Large investors have recently bought and sold shares of the business. Barclays PLC bought a new position in OnKure Therapeutics during the fourth quarter valued at $75,000. OMERS ADMINISTRATION Corp purchased a new position in OnKure Therapeutics in the 4th quarter worth about $104,000. Walleye Capital LLC bought a new position in OnKure Therapeutics during the 4th quarter worth about $116,000. Two Sigma Advisers LP bought a new position in OnKure Therapeutics during the 4th quarter worth about $122,000. Finally, Shay Capital LLC bought a new position in OnKure Therapeutics during the 4th quarter worth about $129,000. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.